The impact of thromboprophylaxis on cancer survival: Focus on pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 579-588

  Mandalà, Mario ^a   Tondini, Carlo ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

anticoagulation; cancer; pancreatic cancer; prognosis; venous thromboembolism

Indexed keywords

BEVACIZUMAB; BLOOD CLOTTING FACTOR 7A INHIBITOR; CAPECITABINE; CISPLATIN; DALTEPARIN; ENOXAPARIN; GEMCITABINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN C; NADROPARIN; PCI 27483; PLACEBO; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN;

ADVANCED CANCER; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD CLOTTING; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; METASTASIS POTENTIAL; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; VENOUS THROMBOEMBOLISM;

EID: 79955122630     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.184     Document Type: Review

References (61)

1. Kosuri K, Muscarella P, BeKaii-Saab TS. Updates and controversies in the treatment of pancreatic cancer. Clin. Adv. Hematol. Oncol. 4, 47-54 (2006). (Pubitemid 43173714)
2. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am. J. Cancer 34, 566-585 (1938).
3. Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH. Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb. Haemost. 95, 541-545 (2006).
4. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb. Haemost. 87, 575-579 (2002). (Pubitemid 34302943)
5. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol. 24, 484-490 (2006). (Pubitemid 46630468)
6. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur. J. Cancer 42, 410-414 (2006). (Pubitemid 43132898)
7. Mandala M, Reni M, Cascinu S et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann. Oncol. 18, 1660-1665 (2007). (Pubitemid 47506252)
8. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
9. Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of Phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol. 47, 337-346 (2008). (Pubitemid 351414919)
10. Mandalà M, Falanga A, Piccioli A et al.; for the working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology. Crit. Rev. Oncol. Hematol. 59, 194-204 (2006). (Pubitemid 44403960)
11. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300, 2277-2285 (2008).
12. Falanga A, Rickels FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost. 25, 173-182 (1999). (Pubitemid 29227146)
13. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest. 112, 853-862 (2003). (Pubitemid 38063743)
14. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 124, 58S-68S (2003).
15. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg. 82, 1101-1104 (1995).
16. Nitori N, Yoshinori I, Nakanishi Y et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 11, 2531-2539 (2005). (Pubitemid 40569450)
17. Khorana AA, Ahrendt SA, Ryan CK et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 13, 2870-2875 (2007). (Pubitemid 46849560)
18. Abid Hussein MN, Meesters EW, Osmanovic N et al. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J. Thromb. Haemost. 1, 2434-2443 (2003).
19. Ghosh A, Li W, Febbraio M et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest. 118, 1934-1943 (2008). (Pubitemid 351632395)
20. Muller I, Klocke A, Alex M et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 17, 476-478 (2003).
21. Tilley RE, Holscher T, Belani R et al. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res. 122, 604-609 (2008).
22. Del Conde I, Bharwani LD, Dietzen DJ et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J. Thromb. Haemost. 5, 70-74 (2007). (Pubitemid 44921069)
23. Hron G, Kollars M, Weber H et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost. 97, 119-123 (2007). (Pubitemid 46242392)
24. Tesselaar ME, Romijn FP, Van Der Linden IK et al. Microparticle- associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 5, 520-527 (2007). (Pubitemid 46680685)
25. Zwicker JI, Liebman HA, Neuberg D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 15, 6830-6840 (2009).
26. Prandoni P, Falanga A, Piccioli A. Cancer and venous thrombosis. Lancet Oncol. 6, 401-410 (2005).
27. Wojtukiewicz MZ, Rucinska M, Zacharski LR et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb. Haemost. 86, 1416-1420 (2001). (Pubitemid 34007513)
28. Balzarotti M, Fontana F, Marras C et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol. Res. 16, 245-250 (2006). (Pubitemid 46211728)
29. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313, 355-364 (1992).
30. Yu J, Rak JW, Klement G, Kerbel RS. VEGF isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. 62, 1838-1846 (2002). (Pubitemid 34408511)
31. Mousa SA, Linhardt R, Francis JL et al. Anti-metastatic effect of non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 96, 816-821 (2006). (Pubitemid 44883824)
32. Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res. 2, S66-S71 (2010).
33. Borsig L, Wong R, Feramisco J et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumour metastasis. Proc. Natl Acad. Sci. USA 98, 3352-3357 (2001). (Pubitemid 32220849)
34. Debergh I, Van Damme N, Pattyn P et al. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br. J. Cancer 102, 837-843 (2010).
35. Marchetti M, Vignoli A, Russo L et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb. Res. 121, 637-645 (2008). (Pubitemid 351305285)
36. Khorana AA, Sahni A, Atland OG, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23, 2110-2115 (2003). (Pubitemid 37433208)
37. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11, 7003-7011 (2005). (Pubitemid 41428760)
38. Maraveyas A, Ettelaie C, Echrist H et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation Fibrinolysis 21, 452-458 (2010).
39. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458-464 (2006).
40. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850 (2000). (Pubitemid 32104130)
41. Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53, 2046-2052 (1984). (Pubitemid 14101772)
42. Chahinian AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol. 7, 993-1002 (1989). (Pubitemid 19196521)
43. Maurer LH, Herndon JE 2nd, Hollis DR et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol. 15, 3378-3387 (1997). (Pubitemid 27485858)
44. Lebeau B, Chastang C, Berchot JM et al.; 'Petites Cellules' Group. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74, 38-45 (1994). (Pubitemid 24187607)
45. Altinbas M, Coskun M, Er O et al. A randomized trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J. Thromb. Haemost. 2, 1266-1271 (2004). (Pubitemid 40186120)
46. Akl EA, van Doormaal FF, Barba M et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst. Rev. 3, CD006652 (2007).
47. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110, 1149-1161 (2007). (Pubitemid 47312882)
48. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin therapy with dalteparin, and survival in advanced cancer. The Fragmin Advanced Malignancy Outcome Study (FAMOUS).J. Clin. Oncol. 22, 1944-1948 (2004). (Pubitemid 41095187)
49. Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135 (2005). (Pubitemid 46218704)
50. Sideras K, Schaefer PL, Okuno SH et al. Low-molecular-weight heparin in patients with advanced cancer: a Phase 3 clinical trial. Mayo Clin. Proc. 81, 758-767 (2006). (Pubitemid 43839491)
51. Haas SK, Kakkar AK, Kemkes-Matthes B et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC studies. J. Thromb. Haemost. 3(Suppl. 1), (2005) (Abstract OR059).
52. Buller HR, Prins MH. Late breaking clinical trial: the effect of the low-molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the Inpact Investigators).J. Thromb. Hemost. 7(Suppl. 2) (2009) (Abstract LB-MO-004).
53. Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943-949 (2009).
54. Lapierre F, Holme K, Lam L et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6, 355-366 (1996). (Pubitemid 26160105)
55. Zacharski LR, Wojtukiewicz MZ, Costantini V et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Hemostas. Thromb. 18, 104-116 (1992).
56. Nakchbandi W, Müller H, Singer MV, Löhr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand. J. Gastroenterol. 41, 1095-1104 (2006).
57. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am. J. Clin. Oncol. 22, 187-190 (1999). (Pubitemid 30263351)
58. von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb. Haemost. 98, 434-439 (2007). (Pubitemid 47250248)
59. Icli F, Akbulut H, Utkan G et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol. 95, 507-512 (2007). (Pubitemid 46709395)
60. Maraveyas A, Waters J, Roy R et al. Wedgwood gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised Phase IIB trial (the UK FRAGEM study).Proceedings of: ECCO. Eur. J. Cancer 7, 362 (2009) (Abstract 6503).
61. Riess H, Pelzer U, Opitz B et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO 004. Proceedings of: ASCO. J. Clin. Oncol. 28, 15s (2010) (Abstract 4033).